Summary The NAD(P)H quinone oxidoreductase (NQ01 EC 1.6.99.2) is an important biotransformation enzyme system that is also known to metabolize important novel chemotherapeutic compounds. The gene that codes for this enzyme has recently been found to be polymorphic in humans. Here, we describe the ethnic distribution of the polymorphism and note that this may have implications for anti-tumour drug development and use.
The ability of NAD(P)H quinone oxidoreductase (NQO1: EC 1.6.99.2) to bioactivate anti-tumour quinones as well as the elevated NQO1 activity in certain tumours has led to a considerable focus on NQO1 in enzyme-directed drug development (Riley and Workman, 1992; Workman, 1994; Ross et ala, 1993 Ross et ala, , 1994 1996a) . NQOl has been shown to bioactivate both mitomycin C (Siegel et al, 1990) and E09 (Walton et al, 1991) . Correlations between NQO1 activity and either mitomycin C or E09 sensitivity have been described in cellular systems (Riley and Workman, 1992; Workman, 1994; Ross et al, 1996) but, more recently, significant correlations between NQOl activity and mitomycin C and E09 sensitivity have been demonstrated in 69 cell lines in the NCI human tumour cell line panel (Fitzsimmons et al, 1996) . The cytotoxicity of streptonigrin has also been reported to exhibit an excellent correlation with NQO1 activity in cell lines of the NCI panel (Paul et al, 1994) . One significant implication of this work is that knowledge of a particular tumour's level of activating or deactivating enzymes may help in the selection of patients to receive specific anti-cancer therapies, and thereby achieve improved therapeutic selectivity. An important consideration in the development of these approaches is the possible effects of inherited variation in the genes encoding bioreductive enzymes. A further aspect in assessing the general applicability of these strategies is the genetic differences related to the racial and ethnic constitution of patient populations.
Recently, a C to T transition at basepair 609 of exon 6 in the gene encoding NQO1 has been described (Traver et al, 1992; Rosvold et al, 1995; Ross et alb, 1996) . The variant allele is thought to code for a proline to serine amino acid substitution in codon 187 and is associated with a loss of NQO1 protein and enzyme activity (Traver et al, 1992; Rosvold et al, 1995; Ross et alb, 1996) . The polymorphic NQO1 enzyme is a dimeric FADcontaining cytosolic protein that catalyses the two-electron reduction of a variety of quinone compounds (Riley and Workman, 1992; Workman, 1994; Ross et al, 1993 Ross et al, , 1994 . NQO1 functions as a mechanism for the reductive activation of a growing number of chemotherapeutic agents (Table 1) .
METHODS
Because of the increasingly prominent role of bioreductive drugs in cancer chemotherapy and the potential for genetic heterogeneity, we examined the ethnic variation in the prevalence of the NQOI polymorphism in 529 healthy subjects including Caucasians, Hispanics, African-Americans and Asians.
We used a polymerase chain reaction (PCR)-based approach for genotyping; briefly, a 211-bp PCR fragment was amplified from DNA isolated from whole blood using the sense primer (5'-TCCTCAGAGTGGCATTCTGC-3') and antisense primer (5'-TCTCCTCATCCTGTACCTCT-3'). The variant allele is detected using a Hinfl restriction digest run on 1.8% agarose gels. The African-American, Mexican-American and Caucasian individuals were healthy adult control subjects participating in lung cancer case-control studies. The Asian participants were healthy workers in Korea or participants in a longitudinal study of reproduction in mainland China. PDZQ, 2,5-diaziridinyl-3-phenyl-1,4-benzoquinone; MeDZQ, 2,5-diaziridinyl-3,6-dimethyl-1,4-benzoquinone; E09,3-hydroxymethyl-5-aziridinyl-1 -methyl-2-(1 H-indole-4,7 dione)-propenol; CB1 954, 5-(aziridin-1-yl)-2,4-dinitrobenzamide. aAIl compounds are bioactivated by NOO1 except tirapazamine, which is detoxified by NQO1. (Traver et al, 1992; Rosvold et al, 1995; Ross et al, 1996) . Therefore, our results would predict that 5-20% of patients (depending upon ethnicity) will have diminished metabolic activation of bioreductive compounds. This could adversely affect the outcome of such therapies because the tumour-specific action of these agents is thought to depend on increased expression of NQOl in tumours compared with normal tissue. (Rothman et al, 1996) . Hence, the dose-limiting toxicity of bioreductive drugs could also be affected by the NQO1 polymorphism, and could vary with its ethnic distribution. Long-term complications of cancer chemotherapy include the induction of second tumours (Platz et al, 1996) . For example, combination therapy for breast cancer including mitomycin C and mitoxantrone is known to carry a risk for secondary leukaemia (Philpott et al, 1993) . Investigation of the association of NQO1 genotypes with adverse outcome could assist in ongoing efforts to select those patients most likely to benefit from a particular drug or combination of drugs.
Although our data show that the NQOI polymorphism is common, they also indicate significant ethnic differences in allele frequencies; homozygous variants were fourfold more common among Asians compared with Caucasians. Importantly, it is also well known that, for some cancers, the success of treatment is influenced by race and ethnicity (Elledge et al, 1994; Modiano et al, 1995) . For example, Berenberg (1991) has suggested that differences in drug distribution, elimination and metabolism related to genetics could explain the variability in outcome of treatment for breast carcinoma identified between Asian and Caucasian women. Our results emphasize the importance of considering the genetic heterogeneity of diverse patient populations in developing and evaluating bioreductive agents used in cancer chemotherapy.
